Prolocor Announces Appointment of Edward L. Rosen to Its Board of Directors

Prolocor Logo
Prolocor Logo

PHILADELPHIA, March 9, 2023 (Newswire.com) - Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa on the surface of platelets, today announced that Edward L. Rosen has joined the company's Board of Directors. Rosen is a highly accomplished and well-respected industry expert and has held numerous senior-level positions during his illustrious career. 

Most recently, Rosen served as Chief Strategy & Commercial Officer at Clinical Genomics, where he generated and implemented an integrated commercial strategy, delivered successful IP licensing, and oversaw efforts that gained Medicare and Medicare Advantage reimbursement coverage. Prior to joining Clinical Genomics, he served as Executive-in-Residence at Columbia University (Office of Technology Ventures), where he collaborated with entrepreneurs and inventors to facilitate the transfer of research innovations from the lab to the market, as well as supporting start-up efforts across therapeutic, diagnostic and device applications. Earlier in his career, Rosen was co-founder, President and CEO of Elucida Oncology, where he built the company through securing financing to advance its programs. Rosen also spent nearly 20 years with Johnson & Johnson and Smith & Nephew in various positions, departing as Worldwide Vice President of Marketing at Mentor Worldwide, a Johnson & Johnson company.

"We are extremely excited to welcome Ed to Prolocor's Board of Directors," said Dr. Peter DiBattiste, co-founder and CEO of Prolocor. "Ed brings a tremendous wealth of commercialization experience and a solid track record of success. Given his expertise in the medical device, therapeutics, and diagnostics realm, we are confident that Ed can meaningfully contribute to the strategic focus for Prolocor."

ABOUT PROLOCOR, INC.

Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets. For more information on Prolocor, please visit the company's website at www.prolocor.com and follow us on LinkedIn. 

Contact Information:
Mika Stojanovic
Managing Partner, TNG Creative LLC
mika@naissos.com


Original Source: Prolocor Announces Appointment of Edward L. Rosen to Its Board of Directors